Deborah Zarin retweeted
Screening all kids 8-18 for anxiety is dumb/dangerous idea:
1)Causes massive false positive overdiagnosis/stigma/misuse of meds
2)Not enough clinicians to treat kids identified
2)Drains resources better used to improve kid's lives/education
3)Neglects dire needs of severely ill
An influential group of U.S. experts has recommended screening all children ages 8 and older for anxiety, saying the latest research supports early intervention for younger kids.
More than 7% of children ages 3 to 17 have diagnosed anxiety, the CDC says. nyti.ms/3EcNA0C
Deborah Zarin retweeted
So last week I was at CHEST, a meeting of respiratory docs and < 5% in masks. Now I am at #SMDM22 , a meeting of experts in tradeoffs, spillover effects and social welfare, and 90 pct in masks.
I feel like there is a learning here.
Deborah Zarin retweeted
U.S. Senators demand rapid disclosure of all NIH clinical trial results
-> finally policy makers are waking up to the immense cost of federally funded research waste in medicine
transparimed.org/single-post…
Deborah Zarin retweeted
Belfast and Edinburgh reduced their speed limits from 30 mph to 20. The result:
"The main outcome of these schemes was a reduction in road casualties at all levels of severity."
pubmed.ncbi.nlm.nih.gov/3617…
Deborah Zarin retweeted
Great exposé of the Medicare Advantage grift. Any wonder that the "hottest" heath care startups are just fancy MA plans?
Fraud in MA could be as large as the budget of the FBI, EPA and federal prison system combined.
thanks @sangerkatz @ReedAbelson
nytimes.com/2022/10/08/upsho…
Deborah Zarin retweeted
Seems like a terrible idea. We want Congress to give regulatory agencies the authority to make decisions - esp those that impact public health - using best science/evidence, not to be hamstrung when Congress is unhappy with the decisions. pharmaphorum.com/?p=99430 via @pharmaphorum
Deborah Zarin retweeted
The newly approved ALS drug is overpriced and may not work. Otherwise the FDA is doing great! @lisamjarvis bloomberg.com/opinion/articl… via @opinion
Deborah Zarin retweeted
3. AMX0035: 1 study, stat sig results re: fxnl decline on co's analysis not FDA's, survival benefit in OLE
I get excitement for another option+hope this 1 works. But note this is the assortment of tx options produced by low FDA approval standards. 2/2
accessdata.fda.gov/scripts/c…
Deborah Zarin retweeted
Today the @nytimes is publishing the first two installments in a series called "Profits Over Patients."
It's about how tax-exempt hospitals have strayed from their charitable missions for the sake of fatter profits – with profound consequences for the US healthcare system. 🧵
Agree, agree, agree!
Deborah Zarin retweeted
The return on investment to the drug industry of FDA user fees is in billions of dollars. PDUFA is all about how fast can FDA approve drugs, and not about if they help patients. @FDA_Drug_Info F.D.A.’s Drug Industry Fees Fuel Concerns Over Influence nytimes.com/2022/09/15/healt…
Deborah Zarin retweeted
The proportion of randomized controlled trials that inform clinical practice elifesciences.org/articles/7… via @KimmelmanJ et al Very disappointing!
Deborah Zarin retweeted
New paper: Many #clinicaltrials fail to inform clinical practice
elifesciences.org/articles/7… @questbih @SwissClinTrial
Deborah Zarin retweeted
🚨📣💊Want to work w/ me, @reshmagar, @cmrherder, @jsross119? Now's your chance! I'm hiring a post-doc in pharma policy, law, and ethics to join me @PennMEHP. Project will examine the feasibility of post-market trials to confirm drug benefit (and more!).
med.upenn.edu/apps/my/bpp_po…
Deborah Zarin retweeted
Moreover, the tri-modal distribution found in this analysis was based on an exploratory analysis. Moreover, this analysis was not able to determine which patients can expect a meaningful drug effect and which not. Thus, we still don't know who this 15% of users are
Deborah Zarin retweeted
I look forward to the Court's climate policy plans ... they have a life-threatening challenge ahead of them
Deborah Zarin retweeted
Most interventions have modest treatment effects. The challenge is to separate modest effects from no effects - hence RCTs.
Of course, observational analyses of treatment effects can give you the right answer. But it is impossible to know if they have given you the right answer.
Deborah Zarin retweeted
NEJM's "policy about transparency is not particularly transparent, and its policy about limiting the level of conflict of interest for writers of editorials is not enforced"
statnews.com/2022/05/19/nejm… @Mezis_eV @HealthSenseUK @Spinwatch
Deborah Zarin retweeted
The accelerated approval “bargain” is access now, confirmation later. Legislation should firm up post market requirements, not weaken them 🤦🏻♀️
This is troubling - we've asked for it to be struck as the underlying concept behind accelerated approval is requiring sponsors to complete postapproval studies to confirm clinical benefit. Relying on @US_FDA to do this regardless in the face of sponsor pressure isn't enough.